Investigational Drug Information for GDC-0917
✉ Email this page to a colleague
What is the drug development status for GDC-0917?
GDC-0917 is an investigational drug.
There have been 189 clinical trials for GDC-0917.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are seven US patents protecting this investigational drug and one hundred and ninety international patents.
Summary for GDC-0917
| US Patents | 7 |
| International Patents | 190 |
| US Patent Applications | 71 |
| WIPO Patent Applications | 52 |
| Japanese Patent Applications | 25 |
| Clinical Trial Progress | Phase 3 (2016-12-13) |
| Vendors | 26 |
Recent Clinical Trials for GDC-0917
| Title | Sponsor | Phase |
|---|---|---|
| Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With ER[+]/HER2[-] & Ki67≥10% Early Breast Cancer | MedSIR | Phase 2 |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of GDC-6036 in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Hoffmann-La Roche | Phase 1/Phase 2 |
| A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | Genentech, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for GDC-0917
Top disease conditions for GDC-0917
Top clinical trial sponsors for GDC-0917
US Patents for GDC-0917
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GDC-0917 | ⤷ Try a Trial | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) | ⤷ Try a Trial |
| GDC-0917 | ⤷ Try a Trial | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) | ⤷ Try a Trial |
| GDC-0917 | ⤷ Try a Trial | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (New Haven, CT) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GDC-0917
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-0917 | Australia | AU2016330029 | 2035-09-29 | ⤷ Try a Trial |
| GDC-0917 | Australia | AU2021202973 | 2035-09-29 | ⤷ Try a Trial |
| GDC-0917 | Brazil | BR112018005936 | 2035-09-29 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
